HIV Drug (Reverse Transcriptase Inhibitor Lamivudine) Stabilizes Disease Progression in Metastatic Colorectal Cancer; Drug Disrupts Repeat Element Life Cycle; Results Suggest Possible Effectiveness in Other Cancers Also

New clinical research shows that lamivudine, a reverse transcriptase inhibitor widely used in HIV therapy, stopped disease progression in 25% of patients with fourth-line metastatic colorectal cancer. Findings from the trial, published on March 23, 2022 in Cancer Discovery, raise the possibility of an unexpected promising direction in cancer treatment, not just colorectal cancer. The article is titled “Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer.”
Login Or Register To Read Full Story